Insmed reported $21.24M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Cytokinetics USD 24.26M 1.32M Jun/2025
DBV Technologies 461K 323.71K Mar/2025
Dynavax Technologies USD 1.64M 51K Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
Insmed USD 21.24M 1.5M Jun/2025
Novartis USD 289M 14M Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025